Purpose-Autosomal recessive non-syndromic deafness (ARNSD) is characterized by a high degree of genetic heterogeneity with reported mutations in 58 different genes. This study was designed to detect deafness causing variants in a multiethnic cohort with ARNSD by using wholeexome sequencing (WES).
Introduction
Deafness is a global public health concern which affects 1 to 3 per 1,000 newborns. 1 In more than half of the cases with congenital or prelingual deafness, the cause is genetic and most demonstrate an autosomal recessive inheritance pattern. 1 Mutations in 58 different genes have been reported to cause autosomal recessive non-syndromic deafness (ARNSD) (http:// hereditaryhearingloss.org/).
Except for one relatively common gene, GJB2 (MIM 121011), most reported mutations are present in only a single or a few families. 2 Whole-exome sequencing (WES) allows resequencing of nearly all exons of the protein-coding genes in the genome. 3 A growing number of research and clinical diagnostic laboratories are successfully using WES for gene/
Subjects
We included 160 families with at least two members with nonsyndromic sensorineural hearing loss with a pedigree structure suggestive of autosomal recessive inheritance (affected siblings born to unaffected parents with or without parental consanguinity) and GJB2 mutations were negative. Hearing loss was congenital or prelingual onset with a severity ranging from mild to profound. One hundred and one families from Turkey, fifty-four from Iran, two from Mexico, two from Ecuador and one from Puerto Rico were included. Sensorineural hearing loss was diagnosed via standard audiometry in a sound-proof room according to standard clinical practice. Clinical evaluation of all affected individuals by a geneticist and an otolaryngologist included a thorough physical examination, otoscopy, and ophthalmoscopy. Tandem walking and the Romberg test were used for initial vestibular evaluation with more detailed tests if needed based on symptoms and findings. Laboratory investigation included but was not limited to an EKG, urinalysis, and, when available, a high resolution CT scan of the temporal bone or an MRI to identify inner ear anomalies. DNA was extracted from peripheral leukocytes of each member of the family by standard protocols.
Whole-Exome Sequencing
Agilent SureSelect Human All Exon 50 Mb versions 3, 4, and 5 (Agilent Technologies Santa Clara, CA) were used for in-solution enrichment of coding exons and flanking intronic sequences following the manufacturer's standard protocol. The enriched DNA samples were subjected to standard sample preparation for the HiSeq 2000 instrument (Illumina San Diego, CA). The Illumina CASAVA v1.8 pipeline was used to produce 99 bp sequence reads. BWA 6 was used to align sequence reads to the human reference genome (hg19) and variants were called using the GATK (https://www.broadinstitute.org/gatk/) software package. 7 All single nucleotide variants (SNVs) and insertion/deletions (INDELs) were submitted to SeattleSeq137 for further characterization and annotation. Sanger sequencing was used for confirmation and segregation of the variants in each family.
Bioinformatics Analysis
We analyzed WES data using our in house tool (https://genomics.med.miami.edu). Our workflow is seen in Figure 1 . The analysis started with QC checks including the coverage and average read depth of targeted regions, numbers of variants in different categories, and quality scores. All variants were annotated and categorized into known and novel variants.
As previously recommended, we filtered variants based on minor allele frequency of <0.005 in dbSNP141. 8 We also filtered out variants that are present in >10 samples in our internal database of >3,000 exomes from European, Asian, and American ancestries that includes Turkish, Iranian, Mexican, Ecuadorian, and Puerto Rican samples (Figure 1 ). Autosomal recessive inheritance with both homozygous and compound heterozygous inheritance models, and a genotype quality (GQ) score >35 for the variant quality were chosen. 
Discussion
Identifying causative variants in ARNSD is challenging because of (1) the extreme genetic heterogeneity of ARNSD; (2) the presence of different categories of genetic variants such as SNVs, INDELs and CNVs; (3) the presence of a high proportion of non-recurrent mutations and (4) the variability in mutation frequencies in individual ARNSD genes across ethnicities. 18 Consequently, we performed a comprehensive analysis to detect pathogenic SNVs, INDELs and CNVs in the ARNSD genes.
Targeted resequencing allows identification of mutations in the interested gene sets. Recent studies pioneered by Shearer et al. have shown the effectiveness of the targeted resequencing of deafness genes. 8 , 19 An advantage of the targeted resequencing over WES is having better coverage with higher depth and significantly lowered costs, which is suitable for clinical diagnostic labs. However, a main limitation of the targeted sequencing is the need for revalidation of the panel after adding each new gene. In contrast, many laboratories around the world offer WES as a diagnostic tool requiring validation only when a new WES version is introduced. Our analysis using three different versions of an exome capture kit during the four year period shows that the depth of coverage of WES has improved to reliably identify most mutations in known ARNSD genes (Figure 2 ) (Table S1 and Table S4 ). Recently developed WES approaches provide more coverage for genes that are known to cause Mendelian disease. They are expected to cover deafness genes more efficiently. In addition, adding in baits to improve coverage over poorly covered regions may be considered if a better coverage is desired. It was recently shown via targeted sequencing that CNVs are a common cause of deafness. 20 While CNV analysis of the WES data is being still optimized for clinical usage, we integrated two currently available tools, XHMM and CoNIFER into our WES analysis pipeline and identified large OTOA (MIM 607038), STRC (MIM 606440) and PCDH15 (exon 27-28) homozygous deletions in our cohort, supporting a significant role of CNVs to in deafness etiology.
In this study after excluding GJB2 mutations we detected pathogenic variants in the known ARNSD genes in 56% of the studied families. The advantage of this study is to have large multiplex autosomal recessive families (including affected and unaffected children) that can be tested for co-segregation of all variants. While we identified more novel variants than those reported in Table 1 through WES, only those variants co-segregated in the family with deafness were considered pathogenic. Similarly heterozygous variants didn't explain the phenotype since they did not co-segregate with deafness and were not included. WES facilitates the cataloguing of mutations in different populations. Population characteristics such as the rate of consanguineous marriages may affect the distribution of deafness mutations in different populations. As expected, the vast majority of Turkish and Iranian probands from consanguineous marriages are homozygous for the pathogenic variants (Table 2) . However, there is a marked difference between the rates of solved families in Turkey (73%) vs. Iran (24%) ( Figure 3 ). As seen in figure 3 , the distribution of genes is also different between the two countries. In our study, the top five genes explain 39 out of 101 families (39%) in Turkey, while only 10 out of 54 families (19%) in Iran. Moreover, our analysis of the WES data in the unsolved Iranian families shows that there are no common mutations in genes that are not known to be deafness genes (data not shown). Unless there are common mutations in regions that are not well covered by WES, our data suggest that many rare genes are responsible for the majority of hereditary deafness in the Iranian cohort. It is likely that there are undetected rare variants specific to certain ethnicities in Iran. 21 Another advantage of WES is to allow surveying of mutations for founder effects. We detected TMIE c.250C>T (p.R84W) in three unrelated Turkish families, which all shared a flanking haplotype as noted previously. 22 Furthermore MYO15A, MYO7A, SLC26A4, TMPRSS3, ILDR1, OTOF, ESRRB (MIM 602167) and GIPC3 (MIM 608792) genes had recurrent mutations with shared haplotypes indicating founder effects (Table S2 ).
There is no correlation between the size of transcript and number of mutant alleles (Table  S3 ). There may be some deafness genes that are more prone to have mutations. Founder effects appear to play a role because some small genes such as TMIE, ESRRB, and GIPC3 ranked high in mutation frequency because of founder mutations. Some discrepancy between the size of a gene and number of mutations can be explained by the fact that only certain mutations cause nonsyndromic deafness for some genes. For instance, CDH23, PCDH15, MYO7A are big genes but many mutations in those genes cause Usher syndrome (MIM 276900) instead of ARNSD. An interesting example is TMC1 that ranks the 20th based on size but the 5th for mutation frequency. Nonsyndromic deafness is the only phenotype caused by TMC1 mutations and none of the TMC1 mutations are recurrent in our cohort. These may suggest that TMC1 is relatively more prone to have de novo mutations or it is a highly conserved gene and its variants are rarely tolerated.
In conclusion, WES is a an effective tool for identifying pathogenic SNVs, INDELs and CNVs simultaneously in ARNSD genes and provides further analysis of the unsolved families for novel gene discovery. Identification of two novel ARNSD genes 16 , 17 during the course of this study testifies its power.
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Distribution of causative DNA variants in known ARNSD genes according to the family origin (A) and variant categories (B).
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